- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03283228
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
September 12, 2017 updated by: Z A Kamel, Assiut University
- Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
- Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
- CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients.
- CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients
Study Type
Observational
Enrollment (Anticipated)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 46 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Anew diagnosis cases of adult AML
Description
Inclusion Criteria:
Anew diagnosis cases of adult AML
Exclusion Criteria:
- Pediatric AML .
- follow up cases of adult AML
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
CD11b and CD56 markers
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
|
The expression of CD11b and CD56 in newly diadnosed cases of AML
Other Names:
|
|
Haematological parameters in cases of adult AML
Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
|
The expression of CD11b and CD56 in newly diadnosed cases of AML
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CD11b and CD56 marker
Time Frame: 24 month
|
Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
|
24 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
December 1, 2017
Primary Completion (Anticipated)
December 1, 2018
Study Completion (Anticipated)
October 1, 2019
Study Registration Dates
First Submitted
August 27, 2017
First Submitted That Met QC Criteria
September 12, 2017
First Posted (Actual)
September 14, 2017
Study Record Updates
Last Update Posted (Actual)
September 14, 2017
Last Update Submitted That Met QC Criteria
September 12, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Myeloid Leukemia Markers
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.